Medical

First Alzheimer's Drug to Slow Disease Progression Approved in Switzerland

In a landmark decision, Swissmedic has authorized Donanemab, the first drug proven to slow the cognitive decline associated with Alzheimer's disease. The approval offers new hope for patients in the early stages of the illness, though questions surrounding health insurance coverage remain.